AINEWS
A "pharmacy in your gut" is years off. The toolkit to build it just arrived.
Researchers at Washington University used CRISPR to genetically engineer a hookworm species that resists standard lab cultivation.
Researchers at Washington University used CRISPR to genetically engineer a hookworm species that resists standard lab cultivation.
A new paper has done something parasitologists have wanted for a decade: it has put a working genetic-engineering toolkit into a hookworm species that resists standard lab cultivation. The June 3 Nature Communications paper from Makedonka Mitreva's lab at Washington University School of Medicine in St. Louis uses CRISPR to add a human gene to Ancylostoma ceylanicum, a rodent hookworm that also infects people.
The gene codes for a small, single-gene version of an antibody that binds tetrodotoxin, a pufferfish poison with no approved antidote. Mitreva's team delivered the editing machinery into worm eggs with electroporation, a technique that briefly zaps eggs with an electrical pulse to open them up. Hamsters infected with the engineered worms carried the antibody fragment in their blood. In a test-tube assay, the secreted antibody neutralized roughly 20% of the toxin it was exposed to, according to Science News.
Twenty percent neutralization is not a treatment. It is a signal that the worm makes the molecule, secretes it into the host, and that the molecule still binds its target. Cornelis Hokke, a parasitologist at Leiden University Medical Center, told Science News that the dose produced "might" be far too low to save a hamster that had actually been poisoned. The work, he said, is "moving a bit from science fiction to science."
The story is the toolkit, not the antitoxin. Before this, anyone who wanted to add a gene to a parasitic worm faced a wall: the species that matter for human health mostly refuse to complete their life cycle outside a host, which makes the standard genetic-engineering playbook, the one that works in the lab worm C. elegans, useless. Electroporation of eggs, a trick Mitreva's group adapted from work on other parasites, breaks that wall. Elissa Hallem, a parasitologist at UCLA, told Science News that the technique is "broadly enabling" for many parasitic worms, not just the one used in this study.
What the technique enables is the choice of payload. Tetrodotoxin is the demonstration, not the destination. The Defense Advanced Research Projects Agency, the Pentagon's research arm, funded the work, according to Science News, because TTX sits on its list of biochemical threats, which is why the project has a chemical-defense flavor in addition to a therapeutic one. Mitreva has spent her career on parasitic worms as a public-health problem, and her aspiration, articulated in the Science News write-up, is roughly 50 hookworms acting as a chronic-disease pharmacy for conditions like allergies or obesity, where a steady dose of a biological drug over years might be more useful than a daily pill.
This is where the open questions start to outnumber the answers.
The first is stability. The Nature Communications paper reports that the transgene is expressed, but germline transmission, whether the engineered DNA passes cleanly to the worms' offspring, is the next thing that has to be shown. Without it, every batch of therapeutic worms has to be re-engineered from scratch.
Then the dose has to go up. Twenty percent neutralization in a test tube is a proof of mechanism. A therapeutic version would need orders of magnitude more antibody, or worms that secrete it continuously, or both.
The regulatory layer is its own problem. A living drug that lives in your gut, breeds, and secretes a human protein is not a pill. Regulators will probably treat it closer to a gene therapy than to a biologic, and no agency has approved anything like it. The path through the FDA or its European equivalents will be long and mostly uncharted.
The hardest part to engineer around is the social question. Hookworm therapy is already in controlled human-challenge trials, mostly for autoimmune and allergic conditions, on the theory that hosting a parasite can recalibrate an overactive immune system. The doses used in those trials are tiny and the worms do not last long. A chronic-disease pharmacy of 50 engineered worms is a different ask. It is one thing to swallow a parasite for a few weeks in a clinical trial. It is another to host a population of them, however well-characterized, for years.
Mitreva's paper does not pretend to settle any of this. It is a methods paper dressed in an antitoxin demonstration, and the demonstration is the part that will draw the headlines. The reason to read past the headline is the capability. The capability is the platform. The platform is what other labs will now try to use, and what the small field of parasitic bioengineering, which has spent a decade waiting for exactly this kind of tool, will start to build on.
What to watch next: independent replication of the electroporation protocol in other hookworm species, the first stable transgenic line that passes the edit to its offspring, and the first serious conversation with regulators about how you classify a self-replicating, gut-dwelling biologic. None of those are imminent. All of them are now on the map.